Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3 EUR | -1.64% | -5.36% | -35.76% |
18/03 | Biotalys, Novonesis Sign Deal to Advance Biofungicide Candidate Development | MT |
18/03 | Biotalys and Novonesis Announces Manufacturing and Commercialization Partnership for EVOCA NG | CI |
Sales 2024 * | 3M 3.21M 268M | Sales 2025 * | 3M 3.21M 268M | Capitalization | 96.47M 103M 8.6B |
---|---|---|---|---|---|
Net income 2024 * | - | Net income 2025 * | - | EV / Sales 2024 * | 32.2 x |
Net cash position 2024 * | - 0 0 | Net cash position 2025 * | - 0 0 | EV / Sales 2025 * | 32.2 x |
P/E ratio 2024 * |
-
| P/E ratio 2025 * |
-
| Employees | 75 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 54.77% |
Latest transcript on Biotalys NV
1 day | -1.64% | ||
1 week | -5.36% | ||
Current month | -2.60% | ||
1 month | -1.32% | ||
3 months | -32.13% | ||
6 months | -5.06% | ||
Current year | -35.76% |
Managers | Title | Age | Since |
---|---|---|---|
Kevin R. Helash
CEO | Chief Executive Officer | 59 | 01/12 |
Douglas Minder
DFI | Director of Finance/CFO | - | 01/21/01 |
Carlo Boutton
CTO | Chief Tech/Sci/R&D Officer | - | 03/22/03 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 62 | 01/13/01 | |
Simon Moroney
CHM | Chairman | 65 | 01/21/01 |
Johan Cardoen
BRD | Director/Board Member | 65 | 01/13/01 |
Date | Price | Change | Volume |
---|---|---|---|
26/24/26 | 3 | -1.64% | 17,511 |
25/24/25 | 3.05 | 0.00% | 6,295 |
24/24/24 | 3.05 | -0.33% | 6,939 |
23/24/23 | 3.06 | -1.92% | 17,600 |
22/24/22 | 3.12 | -1.58% | 12,159 |
Real-time Euronext Bruxelles, April 26, 2024 at 08:40 pm IST
More quotesAnnual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-35.76% | 103M | |
+0.02% | 7.34B | |
+7.85% | 3.17B | |
+9.03% | 843M | |
-3.78% | 357M | |
+14.12% | 296M |
- Stock Market
- Equities
- BTLS Stock